Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 3Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Gynecologic Cancer 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 81S 1 (combination) 55Capecitabine 44apatinib 32Paclitaxel 32Docetaxel 32Irinotecan 27Fluorouracil 22Drug Therapy 21sintilimab 20Cisplatin 20Leucovorin 16Hyperthermic Intraperitoneal Chemotherapy 13XELOX 12Surgical Procedures, Operative 12camrelizumab 10Trastuzumab 10titanium silicide 9Tegafur 9Nivolumab 9Neoadjuvant Therapy 9pembrolizumab 8Laparoscopy 8Gastrectomy 8Folfox protocol 7Chemotherapy, Adjuvant 7toripalimab 6tislelizumab 6Ramucirumab 6Gastroscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Stomach Neoplasms × Enhanced Recovery After Surgery × Clear all
NCT03160924 2020-05-22

The Impact of Enhanced Recovery After Surgery (ERAS) Program on Clinical and Immunological Outcomes for Minimally-invasive Gastrectomy

Chinese University of Hong Kong

Phase 3 Unknown
50 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03121729 2018-04-30

ERASG1

Jinling Hospital, China

Phase NA Unknown
1,000 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡